I have 30+ years in the scientific research of exosomes. In 2007 I discovered and developed the first non-human exosome carrying a mutated form of human tissue factor, which has resulted in the discovery of the first non-human exosome-based drug, which is now the first exosome-based drug to enter PIII clinical trials.
I am a scholar professor at MIT-Harvard Medical School and have entered into an alliance with the Harvard Medical School & Massachusetts Institute
of Technology’s Biomedical Engineering Center in the joint development of Alxerion’s novel exosome technologies for Drug Delivery and New Drug Development
Founder & CEO of Alxerion Biotech Group, including Alxerion Biotech Corporation, Cambridge, MA and LTI Biotech, Buenos Aires, Argentina